Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2024-03-22 Annual Report
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
2023 Annual Report and Accounts
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2023' for Hikma Pharmaceuticals PLC. It contains comprehensive sections including the Executive Chairman's statement, business and financial reviews, sustainability reports, corporate governance, and full audited consolidated financial statements (Income Statement, Statement of Financial Position, and Statement of Cash Flows). This meets the definition of an Annual Report (10-K). FY 2023
2024-03-22 English
Annual Financial Report and Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3406 chars) released via RNS (London Stock Exchange news service). It explicitly states that the 'Annual Report and Accounts for the year ended 31 December 2023' and the 'Notice of the 2024 Annual General Meeting' are being made available to shareholders and provides links to view/download them. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report and provides links rather than containing the full report content, it should be classified as a Report Publication Announcement (RPA). Although it mentions the Annual Report (10-K) and AGM Notice (AGM-R), the document itself is the announcement of their release.
2024-03-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement by the header 'RNS Number : 6878G' and the concluding boilerplate text mentioning RNS and the FCA. The content details transactions (share vesting and sales to cover tax) by Persons Discharging Managerial Responsibilities (PDMRs) within Hikma Pharmaceuticals Plc. This type of mandatory disclosure regarding insider transactions falls under regulatory reporting. Since there is a specific category for 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives, this is the most precise classification. Although it is an RNS filing, DIRS is more specific than the general RNS fallback.
2024-03-13 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a regulatory announcement from Hikma Pharmaceuticals Plc, identified by the 'RNS Number' and the closing statement referencing RNS as the news service of the London Stock Exchange. The content explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR)' regarding the vesting of share awards and subsequent share sales to cover tax obligations for specific executives (Bassam Kanaan, Julie Hill). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (Code: DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2024-03-07 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official notification released via RNS (Regulatory News Service) by Hikma Pharmaceuticals Plc. The content explicitly states the 'Total Voting Rights and Capital' as of a specific date (29 February 2024) and references compliance with the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules. This type of mandatory disclosure regarding the total number of shares with voting rights, often used as a denominator for shareholder notifications, is a standard regulatory announcement. While it relates to capital structure, it is not a financing activity (CAP) or a share repurchase (POS), but rather a periodic regulatory update on voting rights. Since it is a specific regulatory filing that doesn't fit perfectly into the other defined categories (like 10-K, ER, or DIV), and it is clearly an official regulatory release via RNS, the most appropriate classification is the general regulatory filing category, RNS, as it is the primary channel and nature of the communication.
2024-03-01 English
Final Results
Earnings Release Classification · 100% confidence The document explicitly states it reports 'audited results for the year ended 31 December 2023'. It contains detailed financial tables (Revenue, Operating profit, Core results, EBITDA) and a comprehensive strategic review covering all business segments (Injectables, Branded, Generics). This structure and content are characteristic of a full annual financial report. Although it is announced via an RNS number, the document itself is the full annual report, not just a brief announcement of its publication. The closest specific category for a comprehensive annual financial report is '10-K', which is the US SEC equivalent for an Annual Report. Given the context of global filings, '10-K' is the most appropriate classification for a full annual report. FY 2023
2024-02-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.